FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:ACOX1-UBE2E2

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: ACOX1-UBE2E2
FusionPDB ID: 1400
FusionGDB2.0 ID: 1400
HgeneTgene
Gene symbol

ACOX1

UBE2E2

Gene ID

51

7325

Gene nameacyl-CoA oxidase 1ubiquitin conjugating enzyme E2 E2
SynonymsACOX|PALMCOX|SCOXUBCH8
Cytomap

17q25.1

3p24.3

Type of geneprotein-codingprotein-coding
Descriptionperoxisomal acyl-coenzyme A oxidase 1AOXacyl-CoA oxidase 1, palmitoylacyl-CoA oxidase, straight-chainacyl-Coenzyme A oxidase 1, palmitoylpalmitoyl-CoA oxidaseperoxisomal fatty acyl-CoA oxidasestraight-chain acyl-CoA oxidaseubiquitin-conjugating enzyme E2 E2E2 ubiquitin-conjugating enzyme E2ubiquitin carrier protein E2ubiquitin conjugating enzyme E2E 2ubiquitin-conjugating enzyme E2E 2 (UBC4/5 homolog, yeast)ubiquitin-conjugating enzyme E2E 2 (homologous to yeast UBC4/5
Modification date2020031320200327
UniProtAcc

Q15067

Main function of 5'-partner protein: FUNCTION: Catalyzes the desaturation of acyl-CoAs to 2-trans-enoyl-CoAs. First enzyme of the fatty acid beta-oxidation pathway. {ECO:0000269|PubMed:15060085, ECO:0000269|PubMed:17458872, ECO:0000269|PubMed:17603022, ECO:0000269|PubMed:32169171}.; FUNCTION: [Isoform 1]: Shows highest activity against medium-chain fatty acyl-CoAs and activity decreases with increasing chain length. {ECO:0000269|PubMed:17603022}.; FUNCTION: [Isoform 2]: Is active against a much broader range of substrates and shows activity towards very long-chain acyl-CoAs. Is twice as active as isoform 1 against 16-hydroxy-palmitoyl-CoA and is 25% more active against 1,16-hexadecanodioyl-CoA. {ECO:0000269|PubMed:17603022}.
.
Ensembl transtripts involved in fusion geneENST idsENST00000591857, ENST00000537812, 
ENST00000293217, ENST00000301608, 
ENST00000396703, ENST00000425792, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score6 X 6 X 5=18015 X 12 X 6=1080
# samples 1015
** MAII scorelog2(10/180*10)=-0.84799690655495
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(15/1080*10)=-2.84799690655495
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: ACOX1 [Title/Abstract] AND UBE2E2 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: ACOX1 [Title/Abstract] AND UBE2E2 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)ACOX1(73974615)-UBE2E2(23541099), # samples:1
Anticipated loss of major functional domain due to fusion event.ACOX1-UBE2E2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ACOX1-UBE2E2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
ACOX1-UBE2E2 seems lost the major protein functional domain in Hgene partner, which is a cell metabolism gene due to the frame-shifted ORF.
ACOX1-UBE2E2 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneACOX1

GO:0006629

lipid metabolic process

8117268

TgeneUBE2E2

GO:0032020

ISG15-protein conjugation

16428300

TgeneUBE2E2

GO:0070534

protein K63-linked ubiquitination

20061386

TgeneUBE2E2

GO:0070936

protein K48-linked ubiquitination

20061386

TgeneUBE2E2

GO:0070979

protein K11-linked ubiquitination

20061386



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr17:73974615/chr3:23541099)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across ACOX1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across UBE2E2 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000293217ACOX1chr1773974615-ENST00000425792UBE2E2chr323541099+1329559278937219
ENST00000293217ACOX1chr1773974615-ENST00000396703UBE2E2chr323541099+2900559278937219
ENST00000301608ACOX1chr1773974615-ENST00000425792UBE2E2chr323541099+110033049708219
ENST00000301608ACOX1chr1773974615-ENST00000396703UBE2E2chr323541099+267133049708219

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000293217ENST00000425792ACOX1chr1773974615-UBE2E2chr323541099+0.0017241330.9982759
ENST00000293217ENST00000396703ACOX1chr1773974615-UBE2E2chr323541099+0.0003952410.99960476
ENST00000301608ENST00000425792ACOX1chr1773974615-UBE2E2chr323541099+0.0012733390.99872667
ENST00000301608ENST00000396703ACOX1chr1773974615-UBE2E2chr323541099+0.0003757340.99962425

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ACOX1-UBE2E2

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
ACOX1chr1773974615UBE2E2chr32354109933094GIADPDEIMWFKNAGPKGDNIYEWRS
ACOX1chr1773974615UBE2E2chr32354109955994GIADPDEIMWFKNAGPKGDNIYEWRS

Top

Potential FusionNeoAntigen Information of ACOX1-UBE2E2 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ACOX1-UBE2E2_73974615_23541099.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ACOX1-UBE2E2chr1773974615chr323541099559HLA-B45:01DEIMWFKNA0.98870.8485514
ACOX1-UBE2E2chr1773974615chr323541099559HLA-B18:01DEIMWFKNA0.93670.8765514
ACOX1-UBE2E2chr1773974615chr323541099559HLA-B18:05DEIMWFKNA0.93670.8765514
ACOX1-UBE2E2chr1773974615chr323541099559HLA-B18:08DEIMWFKNA0.93140.7646514
ACOX1-UBE2E2chr1773974615chr323541099559HLA-B18:06DEIMWFKNA0.92220.8871514
ACOX1-UBE2E2chr1773974615chr323541099559HLA-B18:03DEIMWFKNA0.92150.8671514

Top

Potential FusionNeoAntigen Information of ACOX1-UBE2E2 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ACOX1-UBE2E2_73974615_23541099.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-0437PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-0437DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-0442PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-0453PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-0455PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-0456PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-0458PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-0465PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-0465DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-0473PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-0473DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1457PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1457DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1501PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1501DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1503PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1504PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1504DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1505PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1505DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1506PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1506DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1507PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1507DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1509PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1509DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1510PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1512PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1512DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1513PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1513DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1515PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1516PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1516DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1518PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1518DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1520PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1520DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1521PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1521DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1522PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1522DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1523PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1524PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1524DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1528PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1528DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1530PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1531PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1532PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1532DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1533PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1533DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1535PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1535DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1536PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1536DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1537PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1537DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1540PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1540DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1541PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1541DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1542PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1542DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1543PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1543DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1545PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1545DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1546PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1546DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1548PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1548DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1549PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1549DPDEIMWFKNAGPKG318
ACOX1-UBE2E2chr1773974615chr323541099559DRB1-1615PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0202EIMWFKNAGPKGDNI621
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0202DEIMWFKNAGPKGDN520
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0202PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0205EIMWFKNAGPKGDNI621
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0205DEIMWFKNAGPKGDN520
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0210EIMWFKNAGPKGDNI621
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0210DEIMWFKNAGPKGDN520
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0210PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0211EIMWFKNAGPKGDNI621
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0211DEIMWFKNAGPKGDN520
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0211PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0212EIMWFKNAGPKGDNI621
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0212DEIMWFKNAGPKGDN520
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0212PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0213EIMWFKNAGPKGDNI621
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0213DEIMWFKNAGPKGDN520
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0213PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0214EIMWFKNAGPKGDNI621
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0214DEIMWFKNAGPKGDN520
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0215EIMWFKNAGPKGDNI621
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0215DEIMWFKNAGPKGDN520
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0215PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0216EIMWFKNAGPKGDNI621
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0217EIMWFKNAGPKGDNI621
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0217DEIMWFKNAGPKGDN520
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0217PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0218EIMWFKNAGPKGDNI621
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0218DEIMWFKNAGPKGDN520
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0218PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0219EIMWFKNAGPKGDNI621
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0219DEIMWFKNAGPKGDN520
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0220EIMWFKNAGPKGDNI621
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0220DEIMWFKNAGPKGDN520
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0220PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0222EIMWFKNAGPKGDNI621
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0222DEIMWFKNAGPKGDN520
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0223EIMWFKNAGPKGDNI621
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0223DEIMWFKNAGPKGDN520
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0223PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0225EIMWFKNAGPKGDNI621
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0225DEIMWFKNAGPKGDN520
ACOX1-UBE2E2chr1773974615chr323541099559DRB3-0225PDEIMWFKNAGPKGD419
ACOX1-UBE2E2chr1773974615chr323541099559DRB5-0204PDEIMWFKNAGPKGD419

Top

Fusion breakpoint peptide structures of ACOX1-UBE2E2

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
1799EIMWFKNAGPKGDNACOX1UBE2E2chr1773974615chr323541099559

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ACOX1-UBE2E2

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN1799EIMWFKNAGPKGDN-7.9962-8.1096
HLA-B14:023BVN1799EIMWFKNAGPKGDN-5.70842-6.74372
HLA-B52:013W391799EIMWFKNAGPKGDN-6.83737-6.95077
HLA-B52:013W391799EIMWFKNAGPKGDN-4.4836-5.5189
HLA-A11:014UQ21799EIMWFKNAGPKGDN-10.0067-10.1201
HLA-A11:014UQ21799EIMWFKNAGPKGDN-9.03915-10.0745
HLA-A24:025HGA1799EIMWFKNAGPKGDN-6.56204-6.67544
HLA-A24:025HGA1799EIMWFKNAGPKGDN-5.42271-6.45801
HLA-B44:053DX81799EIMWFKNAGPKGDN-7.85648-8.89178
HLA-B44:053DX81799EIMWFKNAGPKGDN-5.3978-5.5112
HLA-A02:016TDR1799EIMWFKNAGPKGDN-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of ACOX1-UBE2E2

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
ACOX1-UBE2E2chr1773974615chr323541099514DEIMWFKNATGATGAAATTATGTGGTTTAAAAATGC

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
ACOX1-UBE2E2chr1773974615chr323541099318DPDEIMWFKNAGPKGTGACCCTGATGAAATTATGTGGTTTAAAAATGCTGGACCCAAAGG
ACOX1-UBE2E2chr1773974615chr323541099419PDEIMWFKNAGPKGDCCCTGATGAAATTATGTGGTTTAAAAATGCTGGACCCAAAGGAGA
ACOX1-UBE2E2chr1773974615chr323541099520DEIMWFKNAGPKGDNTGATGAAATTATGTGGTTTAAAAATGCTGGACCCAAAGGAGACAA
ACOX1-UBE2E2chr1773974615chr323541099621EIMWFKNAGPKGDNITGAAATTATGTGGTTTAAAAATGCTGGACCCAAAGGAGACAACAT

Top

Information of the samples that have these potential fusion neoantigens of ACOX1-UBE2E2

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
STADACOX1-UBE2E2chr1773974615ENST00000293217chr323541099ENST00000396703TCGA-BR-A4IY-01A

Top

Potential target of CAR-T therapy development for ACOX1-UBE2E2

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to ACOX1-UBE2E2

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to ACOX1-UBE2E2

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource